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Abstract
The amyloid precursor protein (APP) as well as its homologues, APP-like protein 1 and 2 (APLP1 and APLP2), are cleaved by
a-, b-, and c-secretases, resulting in the release of their intracellular domains (ICDs). We have shown that the APP
intracellular domain (AICD) is transported to the nucleus by Fe65 where they jointly bind the histone acetyltransferase Tip60
and localize to spherical nuclear complexes (AFT complexes), which are thought to be sites of transcription. We have now
analyzed the subcellular localization and turnover of the APP family members. Similarly to AICD, the ICD of APLP2 localizes
to spherical nuclear complexes together with Fe65 and Tip60. In contrast, the ICD of APLP1, despite binding to Fe65, does
not translocate to the nucleus. In addition, APLP1 predominantly localizes to the plasma membrane, whereas APP and
APLP2 are detected in vesicular structures. APLP1 also demonstrates a much slower turnover of the full-length protein
compared to APP and APLP2. We further show that the ICDs of all APP family members are degraded by the proteasome
and that the N-terminal amino acids of ICDs determine ICD degradation rate. Together, our results suggest that different
nuclear signaling capabilities of APP family members are due to different rates of full-length protein processing and ICD
proteasomal degradation. Our results provide evidence in support of a common nuclear signaling function for APP and
APLP2 that is absent in APLP1, but suggest that APLP1 has a regulatory role in the nuclear translocation of APP family ICDs
due to the sequestration of Fe65.
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Introduction
The amyloid precursor protein (APP) is a type I transmembrane
glycoprotein, encoded by a single gene on chromosome 21q21,
which is causally involved in Alzheimer’s disease (AD) [1]. Full-
length APP is processed by a series of proteolytic cleavage
reactions, mediated by the enzymes a-, b- and c-secretase [2].
Cleavage by either a- or b-secretase results in the liberation of the
soluble N-terminal fragments, sAPPa and sAPPb, and the
membrane bound C-terminal fragments, C83 and C99. The C-
terminal fragments are further cleaved by c-secretase, producing
the extensively studied Ab peptide from C99, which is regarded as
a central player in AD [3]. Cleavage of APP C-terminal fragments
by c-secretase at the e-site releases the APP intracellular domain
(AICD), which has been shown to signal to the nucleus and play a
role in transcriptional regulation [4,5,6,7]. AICD-regulated genes
include KAI1, APP, BACE1, neprilysin, and p53 [4,8,9,10,11].
APP is a member of a highly conserved family of glycoproteins,
which includes the APP-like proteins 1 (APLP1) and 2 (APLP2) in
vertebrates, APPL in Drosophila, and APL-1 in C. elegans. APP and
APLP2 are ubiquitously expressed, with high expression in the
brain [12,13], while APLP1 expression is neuron specific [14].
Interestingly, APP-like proteins lack the Ab domain, which is a
feature unique to APP itself [15,16]. Human APLP2 is located on
chromosome 11q23-q25 and exists in two alternatively spliced
forms, one of which, similarly to APP, contains a KPI domain
[15,17,18]. Human APLP1 is located on chromosome 19q13.1
and, as yet, no spliced transcripts have been identified [19,20]. All
three APP family members have been shown to bind both zinc and
heparin [21] and are thought to play an important role in cell
adhesion in both a homo- and heterotypic manner [22,23].
Furthermore, all family members interact with PAT1a via their
basolateral sorting signal, promoting intracellular transport and
increasing the processing of APP/APLPs [24].
Despite the structural homology and conserved domain
structure of APP family members, it has been shown that their
subcellular localization differs strikingly. A recent study by Kaden
et al. showed that APP and APLP2 mainly localize within
intracellular compartments, such as the ER and endosomes, with
only low levels at the plasma membrane. In contrast, APLP1 was
found to mainly localize to the plasma membrane, corresponding
to an increased tendency to form in-trans interactions at cell-cell
contacts, highlighting an important role for APLP1 in cell
adhesion [25]. Further studies investigating the binding of the
APP family to adaptor proteins have also identified differences
between family members. For example, the binding of JIP-1 to
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APP has been shown to result in transcriptional activation,
whereas expression of JIP-1 with APLP1 or APLP2 showed little or
no transcriptional activity [26].
Studies using knockout mice have revealed important insights
into the relationship between different APP family members.
Single knockout for APP, APLP1, or APLP2 cause minor
phenotypes due to a clear redundancy within the APP gene
family [27,28,29]. However, it is also clear that the different family
members exhibit different functions. Mice with both APP and
APLP1 disrupted are viable and fertile, while those that are double
knockout for both APP and APLP2 or APLP1 and APLP2 die
shortly after birth [27,28]. These findings point to an important
developmental role for APLP2 that is required when either APP or
APLP1 are absent. Combined APP and APLP2 double knockout
exhibit a poorly formed neuromuscular junction and reduced
numbers of presynaptic vesicles [30], which supports findings in
Drosophila models with mutant APPL [31], implicating a role for
the APP family in the regulation of synaptogenesis. Triple
knockout mice, lacking all three APP family members, were found
to die soon after birth and display cortical dysplasia, which
resembles human type 2 lissencephaly, and is characterized by
fragmented basal lamina and over-migration of neurons [32]. This
phenotype is very similar to the phenotype reported in Fe65 family
knockout mice [33], highlighting the importance of this AICD-
binding protein in determining the functions of the APP family
members.
Both APLP1 and APLP2, like APP, can be cleaved by a-, b- and
c-secretase, and intracellular domains are released after c-
secretase cleavage at the e-site [34,35,36,37]. Furthermore,
BACE1 cleavage of APLP1 has recently been shown to result in
the formation of an Ab-like peptide that does not aggregate and
can be a surrogate marker for increased b-cleavage in cerebro-
spinal fluid [38]. All three APP family members have been shown
to be cleaved by caspases at their conserved VEVD motif within
the C-terminus, although the significance of this cleavage is still
debated [39,40].
Proteolytic processing of APP, APLP1 and APLP2 by c-
secretase-mediated e-cleavage generates intracellular domains
(ICDs), which are stabilized by binding to the adaptor protein
Fe65 and, when coexpressed with Fe65, can transactivate Gal4-
Tip60 constructs [34,41]. Transgenic mice expressing AICD and
Fe65 are reported to show pathological features of AD [42]. We
have previously shown that AICD is transported to the nucleus by
Fe65 where, together, they bind Tip60 and form spherical nuclear
complexes (AFT complexes), which localize in transcription
factories [4,43]. We have now investigated the nuclear localization
of APLP1 and APLP2 ICDs upon Fe65 and Tip60 coexpression.
Furthermore, we analyzed the differences in subcellular localiza-
tion and turnover of the full-length proteins and their ICDs. We
have identified dramatic differences in both the subcellular
localization and signaling capability of APLP1 compared to the
other two APP family members. Our results provide evidence for a
nuclear signaling function of the APP and APLP2 ICDs and
support a distinct physiological role for APLP1.
Results
ICDs Derived from APP and APLP2, but not APLP1,
Localize to Spherical Nuclear AFT Complexes
The members of the APP family–APP, APLP1, and APLP2–
show a high degree of sequence homology. In particular, the
intracellular domain of APP family members is highly conserved
and contains common motifs such as a caspase cleavage site and a
YENPTY domain for binding of adaptor proteins. We have
previously shown that AICD bound to Fe65 translocates to the
nucleus and forms, together with Tip60, spherical nuclear AFT
complexes [43]. We were therefore interested whether APLP1 and
APLP2 intracellular domains (subsequently referred to as AL1ICD
and AL2ICD) form nuclear AFT-like complexes similar to AICD.
Coexpression of Fe65, Tip60, and APP in HEK cells resulted in
the retention of Fe65-AICD complexes in the nucleus and the
formation of AFT complexes as reported previously [4,44] (Fig. 1A,
top row). For detection of AFT complexes, Tip60 and APP were
fused to fluorescent proteins, while Fe65 was detected by antibody
staining. As already shown in an earlier publication, antibody
access to AFT complexes is restricted due to their density [44].
Therefore the localization of Fe65 to AFT complexes is sometimes
not as clear as observed for the fluorescently tagged proteins.
Similar to AICD, AL2ICD also formed spherical AFT complexes
with Fe65 and Tip60 in the nucleus (Fig. 1A, bottom row).
Surprisingly, AL1ICD did not localize to the nucleus and Fe65
was retained in extranuclear compartments, colocalizing with full-
length APLP1 (Fig. 1A, middle row). Cytosolic retention of Fe65
prevented the redistribution of Tip60 to nuclear spots, resulting in
an accumulation of Tip60 in nuclear speckles. (Further confocal
fluorescence images of HEK and N2a cells expressing APP family
members together with Tip60 and Fe65 are available in Fig. S1
and Fig. S2.).
To exclude the possibility that the observed different nuclear
signaling capabilities of APP family members were due to
properties of the chosen cell line, experiments were repeated in
N2a mouse neuroblastoma cells. Coexpression of Fe65, Tip60,
and APP led to the formation of spherical nuclear AFT complexes
(Fig. 1B, top row). Similar to our observations in HEK cells,
AL2ICD formed AFT complexes (Fig. 1B, bottom row), while
AL1ICD was not detected in nuclear structures and, due to the
sequestration of Fe65 by full-length APLP1, Tip60 was localized to
nuclear speckles (Fig. 1B, middle row).
APP and APLP2 Exhibit Faster Protein Turnover than
APLP1
To further study the subcellular localization of the APP family
members we expressed APP/APLP with N-terminal 3 myc tags,
preceded by the APP signal peptide to ensure membrane insertion,
and C-terminal 3HA tags (Fig. 2A). A GAPDH promoter was
chosen for expression because the GAPDH gene is constitutively
expressed at high levels in almost all tissues and expression of
transgenes via this mammalian promoter yields good expression
that is weaker than with viral promoters. Expression of APP family
members in HEK cells showed a clear intracellular localization to
vesicular structures for APP and APLP2, whereas APLP1 was
mostly localized to the cell membrane (Fig. 2B). The different
subcellular localization of APP and APLP1 was also observed with
coexpression of Citrine-labeled APP and Cerulean-labeled APLP1
constructs (Fig. S3A). Furthermore, fluorescent resonance energy
transfer (FRET) could be observed between APP and APLP2 but
not between APP and APLP1 in HEK cells, primary astrocytes,
and neurons (Fig. S3 B–D). Thus, in addition to the colocalization
of APP and APLP2, these two family members can form
heterodimers.
The N-terminal 3 myc tag-constructs allowed cell-surface
labeling of APP/APLPs on living cells (Fig. 2C). Antibody
incubations were performed at 4uC to inhibit endocytosis that is
dependent on GTPase function. In contrast, exocytosis, which is
promoted by zippering of SNARE proteins mediating vesicle
fusion, is still able to occur in the absence of enzymatic activity.
After 10 minutes of anti-myc antibody incubation we detected
surface labeling for all three APP family members. The strongest
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staining was observed for APLP1. However, after 30 minutes
incubation, APP and APLP2 surface staining reached similar levels
as APLP1. This points towards a higher turnover of APP and
APLP2 compared to APLP1 at the plasma membrane.
To measure the half-lives of the APP family members we
inhibited protein synthesis for different durations. HEK cells were
transfected with C-terminally 3HA-tagged APP/APLP constructs,
all driven by a GAPDH promoter to ensure comparable
expression levels. 24 hours after transfection, protein synthesis
was inhibited with cycloheximide (CHX). Cells were harvested
after the indicated time of cycloheximide incubation and levels of
full-length protein determined by Western blot (Fig. 3A). APP/
APLP full-length levels were normalized to the highly stable a-
tubulin. APP and APLP2 displayed short half-lives of 43 minutes
and 53 minutes respectively, while half-life of APLP1 was higher
than five hours (308 minutes) (Fig. 3B). The much higher stability
of APLP1 is also evident in the left column of figure 3A: despite the
expression of all three family members under the same promoter,
the levels of APLP1 were much higher, again highlighting its
slower turnover.
The N-terminus of ICDs Determines their Nuclear
Signaling Capabilities
To investigate whether differences in nuclear localization
capability of AICD and AL1ICD are mediated by properties of
their extracellular or intracellular domains, we constructed
chimeric APP/APLP1 expression plasmids. ICDs of APP and
APLP1 were joined at the e-cleavage site of APLP1 and APP,
resulting in the chimeric constructs APLP1-AICD and APP-
AL1ICD, respectively (Fig. 4A). Chimeric constructs were
cotransfected with Fe65 and Tip60 in HEK cells and AFT
complex formation was observed by confocal microscopy. APP-
AL1ICD did not form AFT complexes, despite preserved binding
of Fe65 (Fig. 4B, top row). In contrast, nuclear AFT complex
formation was observed in cells transfected with APLP1-AICD.
These results suggest that the formation of AFT complexes is
determined by the properties of the intracellular domain.
Interestingly, the size of AFT complexes formed from APLP1-
AICD appeared to be decreased when compared to AFT
complexes formed from wildtype APP (Fig. 1A, top tow).
Because the chimeric proteins carry a chimeric e-cleavage site it
is possible that absent nuclear signaling of ICDs is due to impaired
c-secretase cleavage. To investigate this possibility, HEK cells
were transfected with APP, APLP1 or the chimeric APP/APLP1
proteins and treated with the c-secretase inhibitor DAPT (Fig. 4C).
DAPT treatment resulted in an accumulation of C-terminal
fragments (CTFs) when compared to non-treated cells, demon-
strating that c-secretase cleavage is not impaired in the chimeric
proteins. In line with the previous experiments using cyclohexi-
mide, increased full-length levels and decreased CTF levels of
APLP1 indicate the slower turnover of APLP1 compared to APP.
Furthermore, these results suggest that the extracellular and/or
transmembrane regions mediate the differences in protein
turnover. To better understand the turnover of APP family
members, wildtype and chimeric APP-transfected HEK cells were
treated with cycloheximide to monitor the turnover of full-length
proteins. As described earlier, APP turnover is much faster than
APLP1 turnover (Fig. 4D). Turnover of the chimeric proteins was
in between that of the wildtype proteins but resembled more
closely the protein carrying the respective extracellular domain.
Together, these results suggest that both extracellular and
intracellular regions determine the turnover of APP family
members. Moreover, it is likely that the decreased AFT complex
formation for APLP1-AICD as compared to APP is due to the
decreased turnover of APLP1-AICD, which would also lead to
decreased AICD levels.
Our results show that nuclear signaling by the APP family
members is determined by properties of the ICDs, which are
highly conserved and share common motifs, such as a caspase
cleavage site and the YENPTY motif (Fig. 5). We reasoned that
the differences in AFT complex formation capability between
APP/APLP2 and APLP1 must derive from single amino acid or
motif differences between the proteins. We identified 17 conserved
residues in AICD and AL2ICD that are not conserved in AL1ICD
and could thus be responsible for nuclear signaling (Fig. 5). To test
this hypothesis, we exchanged individual or multiple residues of
APP by the corresponding residues of APLP1 and investigated
AFT complex formation. Mutation of the NPTY motif to NATA
abolished Fe65 binding as previously reported [6] and prevented
the nuclear translocation of AICD (Fig. 6A, row 2). We
subsequently mutated amino acids sequentially, either alone or
in combination. (See Fig. S4 for a diagram depicting all mutations
and Fig. S5 for corresponding confocal fluorescence pictures.)
Changing all seven non-conserved residues in the C-terminal
region of AICD that is reported to bind to Fe65 [45] did not
disrupt nuclear signaling (Fig. 6A, row 3; APP(7 xmut)). In
contrast, when we inserted the first 12 amino acids of AL1ICD
into the APP sequence (APP(AL1ICD-AICD38)), nuclear signaling
was completely abolished (Fig. 6A, row 4). Further site-directed
mutagenesis were done to identify the minimal set of amino acids
that prevent nuclear localization of AICD. By this means we
discovered that exchange of the N-terminal residues VML to the
corresponding APLP1 residues LLR (APP(VML646LLR)) is
sufficient to ablate AFT complex formation (Fig. 6A, row 5).
Co-immunoprecipitation of streptavidin-binding protein (SBP)-
tagged APP and APP(VML646LLR) showed that Fe65 binding is
not impaired by exchange of N-terminal ICD residues (Fig. 6B).
Since DAPT treatment of cultures transfected with
APP(VML646LLR) resulted in an accumulation of CTFs, we
can also exclude the possibility that the absence of nuclear AFT
complex formation for APP(VML646LLR) is due to disturbed c-
secretase cleavage (Fig. 6C). Interestingly, in DMSO control
treated cells, ICDs derived from APP were detected but not from
APP(VML646LLR) or APLP1.
Proteasomal Degradation Differs between AL1ICD and
AICD
Several reports have demonstrated that AICD is degraded by
the proteasome [46,47], but little is known about AL1ICD and
AL2ICD degradation. We hypothesized that APP family ICDs
have a different protein turnover, resulting in different capabilities
to form nuclear AFT complexes. To confirm proteasomal
Figure 1. ICDs derived from APP and APLP2, but not APLP1, form nuclear AFT complexes. (A) Confocal fluorescence images of HEK cells
transfected with HA-Fe65, CFP-Tip60, and APP-Cit (top row), HA-Fe65, CFP-Tip60, and APLP1-Cit (middle row), HA-Fe65, CFP-Tip60, and APLP2-Cit
(bottom row). (B) Confocal fluorescence images of N2a cells transfected with HA-Fe65, CFP-Tip60, and APP-Cit (top row), HA-Fe65, CFP-Tip60, and
APLP1-Cit (middle row), HA-Fe65, CTP-Tip60, and APLP2-Cit (bottom row). Note the formation of spherical AFT complexes in the nucleus of cells
transfected with APP or APLP2. In contrast expression of APLP1 resulted in accumulation of Fe65 and APLP1 in extranuclear compartments and at the
plasma membrane, whereas Tip60 localized to nuclear speckles. Scale bars represent 13 mm.
doi:10.1371/journal.pone.0069363.g001
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degradation of AICD, we treated HEK cells transfected with APP-
Cit with two previously described proteasome inhibitors, epox-
omicin and MG-132. Treatment with epoxomicin strongly
increased AICD levels, confirming proteasomal degradation of
AICD, while treatment with MG-132 resulted in an increase in
CTF and AICD levels, suggesting that MG-132 inhibits the
proteasome as well as c-secretase when used in higher concentra-
tions, as reported previously [48] (Fig. 7A). To avoid interference
with secretase processing of APP, epoxomicin was used for
proteasomal inhibition in the following experiments. HEK cells
were transfected with APP-Cit, APP(VML646LLR)-Cit, or
APLP1-Cit and treated with epoxomicin for six hours. In control
treated cells, only ICDs generated from APP were detectable,
while epoxomicin increased the ICDs to detectable levels for the
different constructs (Fig. 7 B–C). These results show that the half-
life differs between APP family ICDs and suggest that proteasomal
degradation efficacy is dependent on the N-terminus generated
after c-secretase cleavage.
Next, we asked whether the localization of APP family ICDs
that do not form AFT complexes is changed after epoxomicin
treatment. Both APP(VML646LLR)-Cit and APP-AL1ICD-Cit,
coexpressed with Fe65 and Tip60, formed AFT complexes when
treated with epoxomicin (Fig. 7D). These results show that both
AICD and AL1ICD can be transferred to the nucleus and form
AFT complexes but under normal conditions AL1ICD is degraded
very quickly by the proteasome due to the identity of its N-
terminal residue. In line with this, we showed that AL1ICD with
an N-terminal fusion of Citrine that prolongs the half-life, resulted
in nuclear localization of AL1ICD to AFT-like complexes when
coexpressed with Fe65 and Tip60 (Fig. 8A).
APLP1 Regulates APP Nuclear Signaling
APLP1 does not signal to the nucleus but it nevertheless binds to
Fe65. We therefore investigated the influence of APLP1 expression
on the nuclear signaling of AICD. We used a myc-tagged Tip60 to
be able to coexpress Cerulean and Citrine-tagged APLP1 and
APP. AICD cleaved from APP again translocated to nuclear AFT
complexes in cells coexpressing Tip60 and Fe65 (Fig. 8B). APLP1
bound to Fe65 with higher affinity than Tip60, as seen by the
relocalization of Fe65 away from Tip60 in the nucleus. Conse-
quently, coexpression of APLP1 together with APP, Fe65 and
Tip60, prevented the formation of nuclear AFT complexes that
are clearly seen in cells not expressing APLP1 (Fig. 8B). These
results suggest that although APLP1 does not directly signal to the
nucleus, it influences AICD nuclear signaling via the sequestration
of Fe65.
Discussion
Although the APP family members share a high sequence
homology and undergo similar processing, different properties and
functions of the three proteins have been described [25]. Here, we
provide further experimental evidence for a distinct function of
APLP1 among APP family members, by reporting a unique
nuclear signaling capability for the ICDs of APP and APLP2, but
not APLP1.
We show that the ICDs released from APP and APLP2 localize
together with Fe65 and Tip60 to spherical nuclear complexes. In
contrast, the ICD released from APLP1 does not localize to the
nucleus, although it is able to bind Fe65. We demonstrate that
nuclear localization of AL1ICD is prevented at two steps of
APLP1 processing. Firstly, slower turnover of full-length APLP1
compared to APP results in lower levels of CTFs, which are the
direct precursors of ICDs. Secondly, AL1ICD undergoes faster
proteasomal degradation compared to AICD. Both steps ulti-
mately result in lower levels of AL1ICD. Our results also indicate
that, although APLP1 does not signal directly to the nucleus, it has
a regulatory function in AICD nuclear localization.
The expression of full-length APP or APLP2, together with
Fe65 and Tip60, results in the translocation of their ICDs to
nuclear AFT complexes, which is dependent on cleavage by c-
secretase [4]. In contrast, the ICD derived from APLP1 does not
translocate to the nucleus. APLP1 binds and sequesters Fe65
outside of the nucleus, while Tip60 remains localized in nuclear
speckles. These speckles represent a different nuclear compart-
Figure 2. APP and APLP2 differ in their subcellular localization from APLP1. (A) Schematic presentation of APP/APLP-expression constructs
with N-terminal 3 myc and C-terminal 3HA tags. The 3-myc tag is preceded by the APP signal peptide (SP) to ensure membrane insertion. (B)
Confocal fluorescence images of HEK cells expressing APP (top row), APLP1 (middle row), or APLP2 (bottom row) and stained with anti-myc and anti-
HA antibodies. APP and APLP2 showed a more prominent intracellular localization to vesicular structures, whereas APLP1 mostly localized to the cell
membrane. (C) Confocal fluorescence images of HEK cells expressing APP (top row), APLP1 (middle row) or APLP2 (bottom row) after live antibody
incubation. Incubation of cells with anti-myc antibody at 4uC for 10 minutes results in surface labeling, especially of APLP1. After 30 minutes of anti-
myc antibody incubation, cell surface signals of APP and APLP2 reached a similar strength as APLP1. Cells were counter-stained with anti HA antibody
after fixation. Scale bars represent 13 mm.
doi:10.1371/journal.pone.0069363.g002
Figure 3. APP and APLP2 have a higher protein turnover than
APLP1. (A) Western blot analysis of HEK cells transfected with C-
terminally HA-tagged APP/APLPs after indicated times of protein
synthesis inhibition with cycloheximide (CHX). Western blots were
probed with anti-HA antibody. Note the strong accumulation of APLP1
as compared to APP and APLP2. (B) APP/APLP full-length levels from A
were normalized to a-tubulin. Mean 6 SEM of n= 3 are shown for each
time point. Data was fitted to exponential functions by the least square
approach. R2(APP) = 0.99; R
2
(APLP1) = 0.82; R
2
(APLP2) = 0.98.
doi:10.1371/journal.pone.0069363.g003
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ment to that occupied by nuclear AFT complexes, which
themselves are thought to correspond to sites of transcription
[43]. Of note, AICD and AL2ICD occupy the same nuclear sites
as the transcriptional activator NICD and interactions of AICD
and NICD nuclear signaling have been described [49] (data not
shown). This could indicate that similar genes are regulated by the
ICDs of APP and APLP2. In fact, the analysis of candidate genes
regulated by AICD has shown that neprilysin expression and
activity is reduced in fibroblasts derived from APP or APLP2
knockout mice and is dramatically diminished in cells from double
knockout mice [9]. Likewise, for genes suppressed by AICD, as
reported for LRP1, the expression levels were even stronger in
APP/APLP2-deficient cells compared to single APP knockout cells
[50]. Taking this combined evidence into account, these results
point towards an exclusive function of APP and APLP2 in
transcriptional regulation.
Using cell surface labeling of living cells and determination of
protein half-life time after cycloheximide-induced inhibition of
translation, we clearly show that full-length APP and APLP2 have
a much faster turnover than APLP1. The stability of APLP1 is
evident in different experimental settings and in stark contrast to
the rapid turnover of APP and APLP2, whose rapid turnover
kinetics have also been reported in vivo [51]. Investigation of the
nuclear signaling capabilities of chimeric APP/APLP1 proteins
suggested that nuclear signaling capability is an intrinsic property
of the ICD sequence that is present in APP but not in APLP1. We
Figure 4. Nuclear signaling capability of APP family members is mediated by the intracellular domain. (A) Schematic representation of
wildtype and chimeric APP/APLP1 constructs. (B) Confocal fluorescence pictures of HEK cells cotransfected with HA-Fe65, CFP-Tip60 and the chimeric
constructs APP-AL1ICD-Cit (top row) or APLP1-AICD-Cit (bottom row). Note that AFT complexes are formed in cells expressing APLP1-AICD but not
APP-AL1ICD. Scale bar represents 13 mm. (C) Western blot analysis of HEK cells transfected with wildtype or chimeric APP/APLP1 constructs after 24-
hour treatment with the c-secretase inhibitor DAPT. Western blots were probed with anti-HA antibody and accumulation of CTFs was observed with
all constructs. (D) Western blot analysis of HEK cells transfected with C-terminally HA-tagged APP/APLP after indicated times of protein synthesis
inhibition with cycloheximide (CHX).
doi:10.1371/journal.pone.0069363.g004
Figure 5. APP family members show high sequence homology. Schematic presentation of APP family ICD sequences and APP/APLP1
mutations. c.s.: cleavage site; b.s.: binding site.
doi:10.1371/journal.pone.0069363.g005
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aligned the ICD sequences and identified 17 amino acids that are
conserved between APP and APLP2 but differ in APLP1. To
identify sequence determinants for nuclear signaling capability we
individually or in combination exchanged all amino acids of AICD
with the corresponding APLP1 residues. Out of all single amino
acid and motif changes, only the exchange of the N-terminal
amino acids VML to LLR ablated nuclear signaling of AICD.
APP(VML646LLR) binding to Fe65 and processing by the
secretases were intact, but the resulting ICD levels were much
lower than for the APP-derived ICDs, suggesting different
degradation rates.
It has been reported that AICD is degraded by insulin-
degrading enzyme (IDE), the lysosomal pathway, and the
proteasome, whereas degradation of ALICDs has only been
poorly investigated [47,52]. Here, we show that the ICDs of both
APP and APLP1 are degraded by the proteasome. Proteasomal
degradation of AL1ICD is faster than for AICD. Inhibition of
proteasomal degradation by epoxomicin and the concomitant
increase in ICD levels resulted in the translocation of ICDs derived
from APP(VML646LLR) and the chimeric construct APP-ALICD
to the nucleus. Under normal conditions the ICDs of these
constructs are degraded and do not reach the nucleus. However,
ICDs released from APLP1, even with epoxomicin treatment, did
not translocate to the nucleus. This is probably due to the fact that
APLP1, because of its slower turnover, accumulates to higher
levels that bind and sequester Fe65, making it unavailable for the
transport of AL1ICD to the nucleus. These results suggest that: (a)
nuclear localization is an intrinsic property of all APP family ICDs,
(b) a certain threshold level for ICDs has to be reached for nuclear
translocation to occur, and (c) slow turnover of full-length APLP1
sequesters Fe65, rendering it unavailable for nuclear translocation
of ICDs.
Since the levels and proteasomal degradation of ICDs of
APP(VML646LLR) and APLP1 behave in a similar way, our
results suggest that the proteasomal degradation rate of ICDs is
dependent on their N-terminal residues. Interestingly, work by
Alexander Varshavsky and colleagues has revealed a proteasomal
pathway in which the degradation of a protein is related to the
identity of the protein’s N-terminal residues [53]. According to this
N-end rule, leucine, the N-terminal residue of APLP1, is a
destabilizing residue, whereas valine and methionine, the N-
terminal residues of APP, are stabilizing. Since both, APP and
APLP1 are degraded by the proteasome and carry multiple lysines
that could potentially be ubiquitinated, it is possible that APP
family ICDs, as suggested previously [54], are substrates of the N-
end rule pathway.
Walsh et al. reported higher stability for AL1ICD than AICD
and AL2ICD when ICDs were expressed as soluble forms [37].
Similar to Walsh et al., we observe nuclear signaling for ICDs of
all three APP family members when ICDs are expressed as soluble
proteins (Fig. 8A). The apparent differences in localization for
AL1ICD derived from full length APLP1 and soluble expressed
AL1ICD are not surprising since much higher levels of ICDs are
obtained from soluble expressed AL1ICD. Furthermore, we have
shown that AL1ICD generated by c-secretase cleavage carries N-
terminal residues that influence degradation rate. However, the
expression of soluble ICDs necessitates the addition of a
methionine at the N-termini that is likely to neutralize the
different degradation times of AICD and AL1ICD reported here.
Our results help to explain the profound effects seen in
knockout mouse models of the APP family. Animals with a double
deficiency in both APP and APLP2 die shortly after birth [27,28].
Knock-in mice have been generated to identify the domain of APP
responsible for these effects. Mutation of the first tyrosine residue,
Tyr-682, of the YENPTY motif abolished Fe65 binding, and thus
nuclear signaling by AICD [55]. APP Y682G knock-in mice
Figure 6. N-terminal residues of APP family ICDs are crucial for
nuclear signaling capability. (A) Confocal fluorescence images of
HEK cells transfected with HA-Fe65, CFP-Tip60 and cotransfected with
APP-Cit or the indicated APP-Cit mutation constructs. Scale bar
represents 13 mm. (B) Co-immunoprecipitation of SBP-tagged APP or
APP(VML646LLR) together with HA-tagged Fe65 using Dynabeads. (C)
Western blot analysis of HEK cells transfected with APP-Cit, APLP1-Cit or
APP(VML646LLR)-Cit constructs after 24 hour treatment with the c-
secretase inhibitor DAPT. AICD-Cit transfected cell lysate was loaded to
identify ICD bands and the membrane was probed with anti-GFP
antibody.
doi:10.1371/journal.pone.0069363.g006
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crossed to an APLP2 knockout strain were found to be postnatally
lethal with neuromuscular synaptic defects, resembling APP/
APLP2 double knockouts [56]. This points towards a requirement
for AICD/AL2ICD-mediated nuclear signaling in development, a
function that cannot be performed by APLP1. This is further
supported by the fact that knock-in of the sAPPb or sAPPa
ectodomains alone is not sufficient to rescue the synaptic deficits in
APP/APLP2 knockout mice [57,58]. Although the phenotypes in
these mouse models could also originate from other aspects of APP
biology–the Y682G knock-in has a dramatically increased
production of sAPPa and the sAPP knock-ins also lack the Ab
sequence in addition to AICD–the current data combined with
our experimental evidence strongly support a role of nuclear
signaling by AICD and AL2ICD in synapse formation that cannot
be performed by the AL1ICD.
We propose that AL1ICD does not have a direct physiological
role in transcriptional regulation, but through sequestration of
Fe65 by APLP1 this family member might act as a repressor of
AICD-mediated nuclear signaling. We conclude that nuclear
signaling is a prime function of the APP and APLP2 ICDs. Our
results also caution the use of drugs inhibiting APP processing as
treatment for AD because of possible interference with APP/APLP
transcriptional function.
Materials and Methods
Ethics Statement
All animal experiments were performed according to the Swiss
animal protection law (TschG) and approved by the local animal
committee (Kantonales Veterina¨ramt Zu¨rich; license 38/2011).
Expression Constructs
APP-Citrine, HA-Fe65, and CFP-Tip60 expressing constructs
have been described previously [4]. Clones of APLP1 (RZPD,
Heidelberg, Germany) and APLP2 (courtesy of Stefan Kins, TU
Kaiserslautern, Germany) were used to amplify open reading
frames and ICDs and cloned into the pUKBK expression vector
system [59] with either CMV or GAPDH promoters. Proteins
were C-terminally tagged with Citrine (Cit), Cerulean (Cer), or
streptavidin-binding protein (SBP), generating APP-Cer, APLP1-
Cit, APLP1-Cer, APLP2-Cit, APLP2-Cer, and APP-SBP. For the
constructs Cit-AICD, Cit-AL1ICD, Cit-AL2ICD, and Cer-
Figure 7. Nuclear localization of APP family ICDs is regulated by different proteasomal degradation rates. (A) Western blot analysis of
HEK cells transfected with APP-Cit followed by 6 h treatment with indicated concentration of MG-132 or epoxomicin. APP-Cit transfected HEK cells
treated with DMSO or DAPT and AICD-Cit transfected cells were loaded to identify CTFs and AICD bands. Membranes were probed with anti-GFP
antibody. Note that MG-132 inhibits the proteasome and at higher concentrations also c-secretase, whereas epoxomicin is a specific proteasome
inhibitor. (B) Western blot analysis of HEK cells transfected with APP-Cit, APLP1-Cit or APP(VML646LLR)-Cit constructs followed by 6 hours of
proteasome inhibition with epoxomicin or DMSO control treatment. The membrane was probed with anti-GFP antibody and GAPDH was used as a
loading control. In the absence of proteasome inhibition ICDs generated from APP are clearly visible. (C) Quantification of ICD levels from B. Mean 6
SEM of n = 3 are shown (p,0.05, t-test). (D) Confocal fluorescence images of HEK cells transfected with HA-Fe65, CFP-Tip60 and cotransfected with
APP(VML646LLR)-Cit (upper rows) or chimeric APP-AL1ICD-Cit (bottom rows) mutation constructs with 6 hours epoxomicin or DMSO control
treatment. Note that AFT complexes are formed after epoxomicin treatment. Scale bar represents 13 mm.
doi:10.1371/journal.pone.0069363.g007
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AL2ICD fluorescence proteins were fused to the N-terminus of the
respective ICD sequence. To generate Myc-Tip60, CFP was
exchanged with a myc tag. GAPDH promoter driven 3myc-APP-
3HA plasmid was constructed by inserting a 3myc-tag coding
oligonucleotide after the APP signal peptide (SP) by restriction
based cloning. For the corresponding APLP constructs, APP was
replaced by open reading frames of APLP1 and APLP2. APP
residues were changed to APLP1 residues by site-directed
mutagenesis. Chimeric APP/APLP1 constructs, APP-AL1ICD
and APLP1-AICD were derived from APP and APLP1 constructs
by PCR-driven overlap extension as described [60].
Cell Culture & Reagents
Human embryonic kidney cells (HEK-293, HEK) and mouse
neuroblastoma N2a (N2a) were purchased from DSMZ
(Braunschweig, Germany) and cultured at 37uC and 5% CO2 in
Figure 8. APLP1 expression prevents localization of AICD to AFT complexes. (A) Confocal fluorescence images of HEK cells transfected with
HA-Fe65, CFP-Tip60 and Cit-AL1ICD (top row) or Cit-AL2ICD (bottom row). Note the nuclear localization of Al1ICD to nuclear complexes. (B) Confocal
fluorescence images of HEK cells transfected with HA-Fe65, Myc-Tip60 and cotransfected with APP-Cit (top row) APLP1-Cer (middle row) or both
(bottom row). Note that AFT complex formation (arrowhead) was ablated in cells expressing APP as well as APLP1 (arrows). Scale bars represent
13 mm.
doi:10.1371/journal.pone.0069363.g008
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Dulbecco’s modified eagle medium (DMEM; Invitrogen, Carls-
bad, CA, USA), supplemented with 10% fetal calf serum (FCS)
and 1% Penicillin/Streptomycin (Invitrogen). For transfection
Lipofectamine 2000 (Invitrogen) was used according to the
manufacturer’s protocol. Medium was replaced after three hours
and cells fixed or homogenized 20–24 h after transfection if not
indicated differently. To inhibit protein synthesis, cells were
treated with 100 mg/ml cycloheximide (CHX; Sigma-Aldrich, St.
Louis, MO, USA). Epoxomicin (EMD Millipore, Billerica, MA,
USA) or MG-132 (Enzo Life Sciences, Farmingdale, NY, USA)
were used to inhibit the proteasome, and DAPT (1 mM; Sigma-
Aldrich) was used to inhibit c-secretase. Primary cultures were
prepared from cortices and hippocampi of 1-day-old C57Bl/6
mice as described [44].
Immunocytochemistry
Cells were fixed for 20 minutes with 4% paraformaldehyde
(PFA), washed with TBS containing 0.05% Triton X-100 and
blocked for one hour with TBS containing 0.2% Triton X-100,
5% horse serum, and 5% goat serum. Fixed cells were incubated
overnight with mouse anti-myc (Roche, Basel, Switzerland) or rat
anti-HA (Roche) antibodies diluted 1:100 in blocking solution.
After washing, cells were incubated with Cy2, Cy3 or Cy5-
conjugated secondary antibodies (1:250; Jackson Laboratory, Ben
Harbor, ME, USA) and embedded in Mowiol (Sigma-Aldrich).
Live Antibody Incubation
HEK cells were, 24 hours after transfection, incubated with
mouse anti-myc antibodies (1:100; Roche) at 4uC for 10 or 30
minutes. After washing with ice-cold PBS, cells were fixed and
stained for HA and myc tags.
Western Blotting
Cell were lysed in a buffer, containing 150 mM NaCl, 10 mM
Tris pH 7.6, 1% Triton X100, 0.25% NP40, and protease
inhibitor (Roche) and centrifuged for 5 minutes at 14000 rpm
[61]. Equal amounts of supernatants were separated on 10–20%
Tricine gels (Invitrogen). Protein bands were visualized by ECL
(Thermo Scientific, Rockford, IL, USA) using a Fuji LAS 3000
Imager. The following primary antibodies were used in this study:
Anti-HA antibody (1:1000; Roche), anti-GFP (1:1000; Roche),
anti-a-tubulin(1:1000; Sigma-Aldrich), anti-GAPDH (1:2000;
Meridian Life Science, Memphis, TN, USA), anti-APP (1:1000;
Epitomics, Burlingame, CA, USA). Anti-mouse-HRP (1:2000;
Jackson Laboratory), anti-rat-HRP (1:2000; Jackson Laboratory),
and anti-rabbit-HRP (1:2000; Jackson Laboratory) were used as
secondary antibodies.
Dynabeads-Streptavidin Pull-down
Pull-down of proteins fused to streptavidin-binding protein
(SBP) was done as described previously [59]. Cells, transfected
with APP-SBP and HA-Fe65, were lysed in homogenization buffer
(150 mM KCl, 20 mM HEPES pH7.2, 10 mM NaCl, 5%
Glycerol, 1% Triton X-100, 2 mM DTT, 5 mM phenanthroline,
and protease inhibitor) and centrifuged for 10 minutes at 800 rpm.
Supernatant was incubated with Dynabeads-Streptavidin M280
(Invitrogen) for 4 hours at 4uC. Beads were separated with a
magnet and washed four times with homogenization buffer. For
protein elution, beads were incubated with a buffer containing
700 nmol biotin for 30 minutes at 4uC. Equal amounts of protein
elution were loaded on 10–20% Tricine gels.
Confocal Microscopy & FRET Measurements
Images were acquired on a Leica TCS/SP2 confocal micro-
scope (Leica, Wetzlar, Germany) and FRET measurements
performed as described previously [4].
Supporting Information
Figure S1 ICDs derived from APP and APLP2, but not
APLP1, form nuclear AFT complexes in HEK cells.
Confocal fluorescence images of HEK cells transfected with HA-
Fe65, CFP-Tip60, and APP-Cit (row 1–2), HA-Fe65, CFP-Tip60,
and APLP1-Cit (row 3–4), HA-Fe65, CFP-Tip60, and APLP2-Cit
(row 5–6). AFT complex formation was observed in cells
transfected with APP-Cit or APLP2-Cit. In contrast cells
transfected with APLP1-Cit did not show AFT complex
formation. Scale bar represents 13 mm.
(TIF)
Figure S2 ICDs derived from APP and APLP2, but not
APLP1, form nuclear AFT complexes in N2a cells.
Confocal fluorescence images of N2a cells transfected with HA-
Fe65, CFP-Tip60, and APP-Cit (row 1–2), HA-Fe65, CFP-Tip60,
and APLP1-Cit (row 3–4), HA-Fe65, CFP-Tip60, and APLP2-Cit
(row 5–6). AFT complex formation was observed in cells
transfected with APP-Cit or APLP2-Cit. In contrast cells
transfected with APLP1-Cit did not show AFT complex
formation. Scale bar represents 13 mm.
(TIF)
Figure S3 APP family members show different subcel-
lular localization and heterodimerization. (A) Confocal
fluorescence images of HEK cells transfected with APLP1-Cer and
APP-Cit. Top row shows maximum projection and middle row
single sections at different z positions. Note the intracellular
localization of APP and the prominent localization of APLP1 at
the plasma membrane. In contrast, the coexpression of APP and
APLP2 shows a clear overlap and localization to the same
intracellular compartments (bottom row). (B) Confocal fluores-
cence and FRET analysis of primary astrocytes expressing APP
family members. APP-Cit was coexpressed with APP-Cer (top
row), APLP1-Cer (second row), APLP2-Cer (bottom row). (C)
Confocal fluorescence pictures and FRET analysis of HEK cells
expressing APLP1-Cer and APP-Cit (top row), APLP2-Cer and
APP-Cit (bottom row). (D) Confocal fluorescence pictures and
FRET analysis of primary neurons expressing APP-Cer and APP-
Cit (top row) and APLP1-Cer and APP-Cit (bottom row). In
different cell types (B–D) coexpression of APP-Cit and APP-Cer
revealed a strong FRET signal due to the presence of APP
homodimers. Similarly, coexpression of APP-Cit and APLP2-Cer
generated a FRET signal. In contrast, expression of APLP1-Cer
and APP-Cit resulted in minimal FRET signal, indicating the near
absence of APP/APLP1 heterodimerization. Scale bars represent
13 mm.
(TIF)
Figure S4 Schematic presentation of APP family ICD
sequences and APP mutations used in this study.
(TIF)
Figure S5 Replacement of most AICD residues by the
corresponding AL1ICD residues does not ablate nuclear
signaling. Confocal fluorescence images of HEK cells cotrans-
fected with HA-Fe65, CFP-Tip60 and the indicated APP-Cit
mutants. Scale bar represents 13 mm.
(TIF)
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